{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-24-000014","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.229315+00:00","generated_at":"2026-06-05T13:55:59.083487+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myriad Genetics Q4 2023 revenue $197M (+11% YoY); adjusted EPS $0.04; raises FY2024 revenue guidance","bullets":["Q4 revenue $196.6M (+11% YoY); full-year 2023 revenue $753.2M (+11% YoY).","Q4 GAAP EPS $(0.36); adjusted EPS $0.04, first positive adjusted EPS in recent quarters.","Q4 Hereditary Cancer revenue $88.9M (+5% YoY); Prenatal $40.0M (+37% YoY); GeneSight $35.6M (+11% YoY).","FY2024 revenue guidance raised to $820-840M (9-11% growth); adjusted EPS guidance $0.00-$0.05.","Acquired select assets from Intermountain Precision Genomics in Feb 2024, including Precise Tumor and Liquid tests."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-24-000014","json":"https://secwatch.observer/filing/0000899923-24-000014.json","markdown":"https://secwatch.observer/filing/0000899923-24-000014.md","text":"https://secwatch.observer/filing/0000899923-24-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000014/0000899923-24-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000014/mygn-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T13:55:59.083487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f5366b90dfd8a82113b16ca3d80ebaa99680be2","claim":"MYRIAD GENETICS INC reported the three months ended December 31, 2023 results: revenue $197 million, EPS $(0.36). Guidance raised.","evidence_excerpt":"Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/899923/000089992324000014/0000899923-24-000014-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Revenue","value":"$197 million"},{"label":"EPS","value":"$(0.36)"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}